Molecular Pathology and Lung Cancer. A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA
|
|
- Violet Norah Charles
- 5 years ago
- Views:
Transcription
1 Molecular Pathology and Lung Cancer A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA
2 Disclosures Preliminary patent application NGS AMP Fusion (Iafrate, Zheng, Le) ArcherDx: Equity holder, Consultant, Royalties SAB/Consultant: Roche, Chugai, Constellation, DebioPharm, Pfizer
3 Genetic Alterations in Adenocarcinoma Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing, Cell 2012
4 Mutational Profiling in Lung Adenocarcinoma ROS1 1.5% BRAF 2% HER2 2% CTNNB1 2% ALK 3% PIK3CA 4% TP53 5% AKT 1% NRAS 1% RET 1% IDH1 <1% No Mutation ~40% EGFR 15% KRAS 23%
5 Mutation Frequencies in Common Cancers Cancer Genome Group, Broad Institute
6 FDA approved Companion Diagnostics in NSCLC Diagnosis Mutation/Target Drug Diagnotic NSCLC EGFR Erlotinib Gefitinib Afatinib Roche Cobas Qiagen Therascreen Qiagen Therascreen NSCLC EGFR T790M Osimertinib Roche Cobas V2 NSCLC ALK Crizotinib Alectinib Ceritinib NSCLC ROS1 Crizotinib MGH FISH* Abbott FISH; Ventana IHC D5F3 FDA-Approved* FDA-Approved* NSCLC PD1 Pembrolizumab PDL1 IHC (DAKO) Source: FDA website
7 NGS Based Snapshot Panel Anchored Multiplex PCRbased ~190 target amplicons across 40 genes High-quality sequence: - Staggered start sites X median coverage Molecular indexing - Bi-template coverage ~2% analytical sensitivity Fast turn-around (<2 weeks) Cost-effective (<$200 reagents) Small tissue amounts (5-10
8 NGS based Profiling in Lung Adenocarcinoma >85% of samples with detectable driver mutation
9 EGFR Transmembrane receptor tyrosine kinase involved in epithelial development and function Kinase domain mutations in lung ACA linked with non-smoking and response to EGFR TKIs (2004) Resistance to approved TKIs current focus of R&D Zhou and Yao, JTO 2016
10 EGFR kinase domains inhibitors: clinical response in 10% of patients Pre-treatment Gefitinib (Iressa) Erlotinib (Tarceva) 3 months post-iressa Nakagawa K et al., Ann Oncol Jun;14(6):
11 High Response Rate to First Line Anti-EGFR Therapy in Advanced EGFR-mutant Lung Adenocarcinoma Sequist et al., J Clin Oncol May 20;26(15):2442-9
12 EGFR and Iressa Pan-Asia Study (IPASS) Mok et al., NEJM 2009
13 EGFR and Iressa Pan-Asia Study (IPASS) Mok et al., NEJM 2009
14 KRAS Sequencing: What Drugs Not to Use 21-kDa GTPase involved in signal transduction in MAPK pathway EGFR Mutations are common in human cancer including in: 90% pancreatic ca, 50% colon ca, 30% lung NSCLC Mutations in KRAS are downstream of EGFR; such tumors would not respond to anti-egfr therapy
15 Mechanisms of acquired drug resistance NSCLC 37 patients w/ EGFR-mutant tumors responded to EGFR inhibitors and later relapsed Sequist et al., Science Translational Medicine, 2011
16 EGFR T790M mutation is associated with EGFR TKI resistanc The T790M mutation causes steric hindrance that prevents TKI binding Mutations are common cause of acquired TKI resistance Following mutations in re-biopsy or cfdna can help guide therapeutic decisions
17 T790M Specific Inhibitors Osimertinib (in development Rociletinib) Prior EGFR TKI FDA cleared assay, T790M positive
18 MET amplification mediates EGFR TKI resistance even in presence of EGFR sensitizing mutations
19 NSCLC Case 1 Therapy erlotinib resistance to therapy 1/30/08 3/31/08 (RUL 6.8x4.5 cm) (RUL 2.6x1.8 cm) response to therapy tumor mass reduced by >50% 2/25/09 (RML 2 cm) new nodules developed consistent with recurrence
20 NSCLC Case 1 Molecular Testing Pre-Rx 08 Resistant 09 Therapy Rx on clinical trial FISH analysis: MET gene amplification MET+EGFR inhibitor Engelman et al., Science, 2007 therapy Bean et al., PNAS, 2007 response to therapy tumor mass reduced by ~30%
21 MET-amplified NSCLC (<1% prevalence): Crizotinib response Day 7 Day 25 Dr. Ignatius Ou
22
23 Crizotinib : Benefits of Real-time Screening Crizotinib: Potent & selective ATP competitive oral inhibitor of MET, ALK, and ROS1 kinases and their oncogenic variants Telomere 2p23 region Centromere 3 5 t(2;5) ALK gene breakpoint region ~250 kb ~300 kb
24 ALK FISH in NSCLC Case 1 Telomere 2p23 region Centromere ALK 29.3 EML t(2;5) ALK gene breakpoint region ~250 kb ~300 kb WT (non-split) signal Split signal
25 ALK IHC Comparison in NSCLC Mino-Kenudson et al., CCR 2010
26 ALK rearrangement Histology MGH experience Signet Ring Cells N % None detected 38 32% < 10% 43 36% > 10% 39 32% Nishino M, Mark EG, Iafrate AJ, Mino-Kenudson M
27 Tumor Responses to Crizotinib by Patient Decrease or increase from baseline (%) % reduction PD SD PR CR Best Percent Change in Tumor Size (n=105 evaluable patients) Camidge R et al. Poster 366 presented at the 35 th ESMO, 2010
28 Timeline for PF and ALK in NSCLC PF Inhibits ALK activity PF FIP May PF activity in cells exhibiting ALK fusion in broad screen (MGH- McDermott) Phase III study of Crizotinib in ALK positive NSCLC starts Identification of PF PF demonstrates cytocidal activity in cells exhibiting ALK fusion (Pfizer in house) Discovery of EML4- ALK fusions in NSCLC (CREST) Japan Science & Technology Agency) Objective responses demonstrated in ALK fusion positive NSCLC and IMT FDA Approval of Crizotinib in ALK positive NSCLC
29 ALK inhibitor resistance
30 2 nd Generation ALK Inhibitors: Alectinib
31 Surprising Re sensitization to Crizotinib
32 ROS1 rearrangement in NSCLC
33 ROS1 rearrangement in NSCLC
34 Clinical Characteristics of ROS1 rearranged NSCLC Age, median Smoking All Patients ROS1 (n=18) ALK (n=31) ROS1 NEG (n=1055) P value No. % No. % No. % No. % ROS1 vs. NEG <.001 Never % 14 78% 13 42% % <.001 Light 62 6% 1 6% 1 3% 61 6% Smoker % 2 11% 3 10% % NA 77 7% 1 6% 14 45% 76 7%
35 ROS1-translocated NSCLC (1.5% prevalence): Crizotinib response
36 Summary of Tumor Responses in Evaluable Patients with Advanced ROS1+ + NSCLC* Best change from baseline (%) Best overall response 12 PD SD PR CR Overall response rate = 50% n=20 evaluable patients; 1 CR and 9 PRs Disease control rate = 70% at 8 weeks
37 Actionable Rearrangements in LUNG Tumors Gene Pathway Prevalence NTRK1,2,3 MAPK <1% FGFR1,2,3 MAPK <1% BRAF MAPK <1% ALK MAPK 3 5% ROS1 MAPK 1.5% RET MAPK 1.5% PRKACA camp <1% MET MAPK 3 5% PRKCA camp <1% ERBB4 MAPK <1% PRKCB camp <1% NRG MAPK <1%
38 Detecting Rearrangements Immunohistochemistry Antigen expression in tumor but not in normal Ab availability Ab specificity Qualitative analysis FISH Technically challenging Expert analysis Poor scalability and multiplexing ability RT PCR Requires knowledge of both partners Limited scalablity and multiplexing ability
39 Anchored Multiplex PCR (AMP) Zheng et al. Nat Med 2014
40 Assay Design for ROS1 Translocation
41 Solid Tumor Fusion Assay (50 genes) ADCK4 AKT3 ALK AXL B2M BRAF BRD4 CCDC6 CD74 CHTOP CTBP1 EGFR ERBB2/4 EWSR1 FGFR1 FGFR2 FGFR3 GAPDH INSR INSRR JAK1 JAK2 MAST1 MAST2 MET MUSK NFIB NOTCH1 NOTCH2 NRG1 NTRK1 NTRK2 NTRK3 NUMBL PDGFB PDGFRA PPARG PRKACA RAF1 RET RHOA ROS1 TMPRSS2
42 Solid Fusion Assay ALK 12 ANK3 1 BRAF 2 EGFR 7 EWSR1 1 FGFR2 12 FGFR3 2 FGR 2 JAK2 1 MAML2 4 MAST1 2 MET 18 NFIB 2 NOTCH1 1 NRG1 1 NTRK1 2 NTRK3 2 PRKACA 2 PRKCB 1 RET 21 RNF26 1 ROS1 12 ZFPM2 1 Positive 110 Negative 1118
43 Met exon 14 skipping: RNA or DNA?
44 Case Genomic DNA alteration Deletion in 3 splice site of intron 1 13 (32 bp deletion) Point mutation in 5 splice site of 2 intron 14 (G>A) SNaPShot Age Gender Stage Smoking Status wt 79 wt 65 Female IB Female IV Never Never Histology ADC ADC 3 Not available Point mutation in 5 splice site of 4 intron 14 (G>A) Deletion in 3 splice site of intron 5 13 ( (12 bp deletion) Deletion in 3 splice site of intron 6 13 (14 bp deletion) Deletion in 3 splice site of intron 7 13 (27 bp deletion) Deletion in 3 splice site of intron 8 13 (24 bp deletion) Deletion in 3 splice site of intron 9 13 (10 bp deletion) Point mutation in 5 splice site of 10 intron 14 (G>A) Deletion in 3 splice site of intron (32 bp deletion) wt 73 wt 84 PI3K CTNNB 48 wt 44 wt 78 wt 75 wt 68 wt 69 wt 81 Female IIB Never SQC Female IA Never ADC Female IIA Never ADC Male IV Never SQC Female IB Never SARC Female IA Never ADC Female IV Former ADC Male IIB Never ADC Female IV Never ADC
45 Met Exon 14 Skipping: Crizotinib Response 74 yo Male non-smoker Stage IV adenocarcinoma 3/18/2015 4/19/2015 Failed multiple lines of chemotherapy AMP detected MET exon 14 skipping Crizotinib Heist et al., in press.
46 45 yo Male 30py smoker Stage IV adenocarcinoma Failed multiple lines of chemotherapy AMP detected NTRK1 fusion Clinical trial of entrectinib NTRK Fusions in NSCLC
47 CD74 NRG1 in Mucinous ADC Fernandez-Cuesta L et al, Cancer Discovery 2014
48 Mucinous Adenocarcinoma & KRAS J Mol Diagn 2007;9:320-6.
49 Mucinous Adenocarcinoma & KRAS 90% KRAS All smokers J Mol Diagn 2007;9:320-6.
50
51 KRAS mutation profiling Clin Cancer Res 2014;20:3921-3
52 TP53 mutation 535C>G H179D Reference: 939 Variant: 168 CD74-NRG1 fusion + TP53m Of 50 cases (30 NGS and 20 SNaPShot), only one case had TP53 mutation. In TCGA, of 230 cases, 105 (46%) cases have TP53 mutation.
53 IMA in TCGA Mucinous (n=12) Non mucinous (n=218) TP53 mutant TP53 wild P=0.008
54 Palmetto MAC MolDx Program NSCLC comprehensive genomic profiling policy (81445, 81455) Patient has been diagnosed with advanced (Stage IIIB or IV) NSCLC Patient is a lifetime non-smoker or former light smoker with <15 pack year history of smoking Patient previously tested negative for EGFR, ALK, and ROS1 through non-cgp methods Testing is performed by a lab that satisfies Palmetto GBA s published AV criteria.
55 NGS MAC NGS Program NSCLC panel policy proposal for made with input from 5 academic medical centers Newly diagnosed NSCLC patients with advanced (stage IIIB or IV) NSCLC, who are not treatable by resection or radiation with curative intent, and who are suitable candidates for therapy at the time of testing. No smoking related rules No comment on prior testing No test quality standards
56 Summary Targeted therapies are a part of routine lung cancer management. Managing resistance is the next frontier. No test is perfect FISH, IHC and NGS all have challenges. The best test choice is a mix of performance, TAT, cost and comprehensiveness. NGS panel testing is replacing other molecular assays in mutation/fusion detection in the clinical lab.
57 Characteristics of Lung Cancer Small cell carcinoma Squamous carcinoma >98% smokers Adenocarcinoma >75% smokers Nat Rev Cancer 2007;7: Nat Genet 2012;44:1074-5
58 Genetic Alterations in Squamous Cell Carcinoma Comprehensive genomic characterization of squamous cell lung cancers, Nature 2012
59 Genetic Alterations in Squamous Cell Carcinoma Copy Number Alterations Comprehensive genomic characterization of squamous cell lung cancers, Nature 2012
60 Genetic Alterations in Small Cell Carcinoma Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer, Nature Gen. 2012
61 MiSeq Rearrangement Assay Validation
62 TTF1 (aka Nkx2.1) 38-kDa transcription factor normally expressed in adult thyroid and lung tissue and is essential in lung development Positive by IHC in >75% of nonmucinous lung adenocarcinomas Most common focal amplification in genome-wide analysis TTF1 may have a role in pathogenesis
Molecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationActivity of osimertinib and the selective RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement.
Activity of osimertinib and the selective RET inhibitor in an EGFR-mutant patient with acquired RET rearrangement. Z Piotrowska 1, H Isozaki 1, JK Lennerz 1, S Digumarthy 1, JF Gainor 1, N Marcoux 1, M
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationFusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas
Fusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas Igor Astsaturov Philip Ellis Jeff Swensen Zoran Gatalica David Arguello Sandeep Reddy Wafik El-Deiry Disclaimers Dr. Igor
More informationPersonalized Genetics
Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationCase Studies. Ravi Salgia, MD, PhD
Case Studies Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Associate Director for Clinical Sciences Research City of Hope 04-21-2018 Objectives
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationLiquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationLiquid biopsy in lung cancer: The EGFR paradigm
Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationBeyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy
Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy Oncogenic drivers in NSCLC Certain tumours arise as a result of aberrant activation
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationThe oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC
The oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC Egbert F. Smit Department of Thoracic Oncology, Netherlands Cancer Institute, and Department
More informationGENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)
CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationTARGETED THERAPY FOR LUNG CANCER. Patient and Caregiver Guide
TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Why Targeted Therapy?...2 Lung Cancer Basics...2 Changes in
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationState of the Art in Tumor Profiling
State of the Art in Tumor Profiling Dora Dias-Santagata, PhD, FACMG ddiassantagata@partners.org Translational Research Laboratory Massachusetts General Hospital Harvard Medical School Boston, MA Disclosures
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationGiorgio V. Scagliotti Università di Torino Dipartimento di Oncologia
Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia giorgio.scagliotti@unito.it Politi K & Herbst R. Clin. Cancer Res. 2015; 21:2213 Breast Colorectal Gastric/GE Junction Tumor Type Head
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationMICROSCOPY PREDICTIVE PROFILING
Immunomodulatory therapy in NSCLC: a year into clinical practice Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor to and speaker
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationMET as a novel treatment target- the story of the sleeping beauty. Balazs Halmos M.D. Montefiore Medical Center/Albert Einstein College of Medicine
MET as a novel treatment target- the story of the sleeping beauty Balazs Halmos M.D. Montefiore Medical Center/Albert Einstein College of Medicine MET as a novel treatment target MET as an oncogene MET
More informationDM Seminar. ALK gene rearrangements & ALK targeted therapy in NSCLC Dr Sarat
DM Seminar ALK gene rearrangements & ALK targeted therapy in NSCLC Dr Sarat Introduction Discovery of activating mutations in kinase domain of epidermal growth factor receptor (EGFR) opened a new era of
More informationPersonalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationThe Role of Pathology/Molecular Diagnostic in Personalized Medicine
The Role of Pathology/Molecular Diagnostic in Personalized Medicine Ignacio I. Wistuba, M.D. Jay and Lori Eissenberg Professor in Lung Cancer Director of the Thoracic Molecular Pathology Lab Departments
More informationIntegration of Genomics Into Clinical Pathways. Precision Medicine and Decision Support
Integration of Genomics Into Clinical Pathways Precision Medicine and Decision Support Faculty Andrew Hertler, MD, FACP Chief Medical Officer New Century Health Andrew Hertler, MD, FACP is employed by
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationMolecular Diagnostic Pathology for Solid Tumor Oncology in the Era of Personalized Medicine
Molecular Diagnostic Pathology for Solid Tumor Oncology in the Era of Personalized Medicine George J. Netto MD Departments of Pathology, Urology and Oncology Johns Hopkins University Disclosures No Relevant
More informationSUBJECT: GENOTYPING - EPIDERMAL GROWTH
MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationCorporate Medical Policy
Corporate Medical Policy Proteomic Testing for Targeted Therapy in Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomic_testing_for_targeted_therapy_in_non_small_cell_lung_cancer
More informationMolecular Diagnostics in Lung Cancer
Molecular Diagnostics in Lung Cancer Mutations in lung carcinomas and their impact on diagnosis and treatment With special thanks to: Barbara Chaitin, MD Medical Director, Esoteric Services AmeriPath Orlando,
More information1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationCell-free tumor DNA for cancer monitoring
Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Analysis for Targeted
More informationLung Cancer Biomarkers: A Practical Update
Lung Cancer Biomarkers: A Practical Update Lynette M. Sholl, M.D. Associate Pathologist, Brigham and Women s Hospital Associate Professor, Harvard Medical School Boston, MA Disclosures Consultant for Foghorn
More informationNon-Small Cell Lung Carcinoma - Myers
Role of Routine Histology and Special Testing in Managing Patients with Non- Small Cell Lung Carcinoma Jeffrey L. Myers, M.D. A. James French Professor Director, Anatomic Pathology & MLabs University of
More informationShort Report Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC
IJC Short Report Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC International Journal of Cancer Jinguang Wang 1, Xingya Li 2, Xingyang Xue 3, Qiuxiang Ou Yang W. Shao
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationTargeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations
Review Article Page 1 of 5 Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations Gérard A. Milano Oncopharmacology Unit, EA 3836 UNS, Centre Antoine Lacassagne,
More informationDrug Resistance in ALK- and ROS1-Rearranged Lung Cancers. Alice T. Shaw, MD PhD Director, Center for Thoracic Cancers September 16, 2017
Drug Resistance in ALK- and ROS1-Rearranged Lung Cancers Alice T. Shaw, MD PhD Director, Center for Thoracic Cancers September 16, 2017 ALK and ROS1 are Related Tyrosine Kinases, and Both are Targeted
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationNext-generation sequencing based clinical testing for lung cancer in Japan
Review Article Next-generation sequencing based clinical testing for lung cancer in Japan Masayuki Takeda 1, Kazuko Sakai 2, Kazuhiko Nakagawa 1, Kazuto Nishio 2 1 Department of Medical Oncology, 2 Department
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationNEW FRONTIERS IN THE BIOLOGY OF LUNG CANCER: WHAT INFLUENCES DIAGNOSIS AND THERAPY?
NEW FRONTIERS IN THE BIOLOGY OF LUNG CANCER: WHAT INFLUENCES DIAGNOSIS AND THERAPY? STEVEN M. DUBINETT, MD CHIEF OF THE DIVISION OF PULMONARY AND CRITICAL CARE MEDICINE DIRECTOR, UCLA LUNG CANCER PROGRAM
More informationECMC cfdna consensus meeting
ECMC cfdna consensus meeting State of the art for cfdna technologies 24 th November 2014 Applications of ctdna analysis for drug development Potential of ctdna analysis to: Identify the right patients
More informationLUNG CANCER TREATMENTS UPDATED MAY What you need to know about... targeted therapy
LUNG CANCER TREATMENTS UPDATED MAY 2018 What you need to know about... targeted therapy foreword About LUNGevity LUNGevity is the largest national lung cancer-focused nonprofit, changing outcomes for people
More informationNieuwe targets en cfdna
Nieuwe targets en cfdna dr. A.J. van der Wekken Universitair Medische Centrum Groningen Leek meeting 2017 Disclosure Advisory board: Lilly Boehringer-Ingelheim Pfizer AstraZeneca MSD Lectures: Lilly Boehringer-Ingelheim
More informationLeading the Way to Precision Care: Molecular Diagnostics and Therapeutics in Lung Cancers. Mark G Kris, MD Memorial Sloan Kettering New Amsterdam USA
Leading the Way to Precision Care: Molecular Diagnostics and Therapeutics in Lung Cancers Mark G Kris, MD Memorial Sloan Kettering New Amsterdam USA Molecular Therapeutics in Lung Cancers Financial Disclosures
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationMP Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
Medical Policy BCBSA Ref. Policy: 2.04.143 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 2.04.121 Miscellaneous Genetic and Molecular Diagnostic Tests 2.04.45 Molecular
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationEXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
More informationLihong Ma 1 *, Zhengbo Song 2 *, Yong Song 1, Yiping Zhang 2. Original Article
Original Article MET overexpression coexisting with epidermal growth factor receptor mutation influence clinical efficacy of EGFR-tyrosine kinase inhibitors in lung adenocarcinoma patients Lihong Ma 1
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More information1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
More informationNon-Small Cell Lung Cancer:
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
More informationBalazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center
Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Eli-Lilly Pfizer Astellas Daiichi-Sankyo Oncothyreon Astex Astra-Zeneca Bristol-Myers-Squibb Novartis Roche Boehringer-Ingelheim
More informationNew molecular targets in lung cancer therapy
New molecular targets in lung cancer therapy Giuseppe Pelosi Pathology Division, Science & Technology Park, IRCCS Multimedica, Milan Milan - Italy Advanced lung cancer (IIIB IV) Subtyping Oncogene addiction
More informationMECHANISMS OF 1ST GENERATION RESISTANCE. Byoung Chul Cho, M.D., Ph.D.
MECHANISMS OF 1ST GENERATION RESISTANCE Byoung Chul Cho, M.D., Ph.D. CONFLICT OF INTEREST Research funding: Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST Consulting role: Novartis, AstraZeneca,
More informationDiagnostic test Suggested website label Description Hospitals available
Diagnostic test Suggested website label Description Hospitals available Abbott Molecular Inc, PATHVYSION HER-2 DNA Probe Kit (FISH) PathVysion kit A diagnostic tool used to determine whether a particular
More informationLung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP
Lung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP Professor, Dept of Pathology, Dalhousie University Pulmonary Pathologist and Cytopathologist, QEII HSC Senior Scientist, Beatrice Hunter Cancer
More informationOther Driver Mutations: cmet, B-RAF, RET, NTRK
Other Driver Mutations: cmet, B-RAF, RET, NTRK Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology and Medical Director, Memorial Cancer Institute Clinical Professor of Medicine Herbert Wertheim College
More information5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff
5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff National molecular screening of patients with lung cancer for a national trial of multiple novel agents. 2000 NSCLC patients/year (late
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationKEY FINDINGS 1. Potential Clinical Benefit in Non-Small Cell Lung Cancer with Gefitinib, Erlotinib, Afatinib due to EGFR E746_A750del. 2. Potential Cl
PATIENT INFO SAMPLE REFERING PHYSICIAN COPY TO (if different from ordering) Name: John Smith Date Collected: 10/23/2016 Name: Oncologist, M.D. Name: Pathologist, M.D. DOB: 04/22/1937 Date Received: 10/24/2016
More informationQIAGEN Complete Solutions for Liquid Biopsy Molecular Testing
QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing Christopher Swagell, PhD Market Development Manager, Advanced Molecular Pathology QIAGEN 1 Agenda QIAGEN Solid Tumor Testing and Liquid Biopsy
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Page 1 of 36 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Circulating Tumor DNA
More information